Asset Details
Do you wish to reserve the book?
Ranibizumab and Bevacizumab for AMD
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Ranibizumab and Bevacizumab for AMD
Do you wish to request the book?
Ranibizumab and Bevacizumab for AMD
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Ranibizumab and Bevacizumab for AMD
2011
Overview
To the Editor:
Bevacizumab is the predominant agent used for the treatment of neovascular age-related macular degeneration (AMD) worldwide, and the study by the Comparison of AMD Treatments Trials (CATT) research group (May 19 issue)
1
should have far-reaching influence on global practice patterns.
2
However, considerable uncertainty is likely to remain in Asia, whose population was not addressed by CATT. The unfortunate truth remains that 80% of all new drugs are discovered in the United States and Europe, are tested in subjects of European descent, and are then administered to Asians on the presumption of similar therapeutic response.
3
Increasing evidence suggests . . .
Publisher
Massachusetts Medical Society
